Top Health-care stocks:
Health-care shares were generally unchanged in pre-market trade Thursday.
In health-care stocks news, BIND Therapeutics, Inc. ( BIND ), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins, said Pfizer ( PFE ) exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement.
Shares in the company were unchanged at $4.47 pre-bell. Over the past 52 weeks, the company has traded between $4.09 and $10.75.
Keryx Biopharmaceuticals ( KERX ) Thursday reported that the European Commission has approved Fexeric (ferric citrate coordination complex) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease (CKD), including both dialysis and pre-dialysis patients.
The company's shares surged 18.6% pre-bell to $4.65. Over the past 52 weeks, the company has traded between $3.77 and $17.97.
And Myriad Genetics ( MYGN ) Thursday said it is presenting new data at the 40th European Society for Medical Oncology (ESMO) meeting on the ability of its companion diagnostics to identify the highest number of patients who may benefit from drugs that target the DNA-repair pathway, such as PARP inhibitors.
Shares in the company were unchanged at $39.93 pre-bell. Over the past 52 weeks, the company has traded between $30.30 and $41.81.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.